Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Balversais an oral tyrosine kinase inhibitor for the treatment of non-small cell lung cancer and urothelial carcinoma, among others, and provides a new treatment option for patient···【more】
Article source：Captain MedicineRelease date：2024-08-26Recommended：227
Alpelisib has demonstrated a unique efficacy against PIK3CA mutations in HR/HER2- advanced breast cancer, and the combination with fulvestrant further enhances the anti-tumor effec···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：241
Patients with HR/HER2- advanced breast cancer harboring PIK3CA mutations were significantly delayed in disease progression under the combination of Alpelisib and fulvestrant.What i···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：332
By specifically inhibiting PIK3CA mutations, Apelis provides a novel therapeutic strategy for patients with HR/HER2- advanced breast cancer.What diseases can be treated with Alpeli···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：280
Alpelisib fills a gap in the treatment of HR/HER2- breast cancer, particularly in patients with PIK3CA mutations, and the combination of fulvestrant improves efficacy.Who is Alpeli···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：270
For patients with advanced HR/HER2- breast cancer, the combination of Alpelisib and fulvestrant is a precision treatment for PIK3CA mutations.Who is Alpelisib for?Alpelisib is suit···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：207
As a PIK3CA inhibitor, Alpelisib works synergistically with fulvestrant to significantly improve the prognosis of breast cancer patients with HR/HER2- and PIK3CA mutations.What is ···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：276
Alpelisib effectively inhibits the proliferation of HR/HER2- breast cancer cells by inhibiting the PI3K pathway, which is especially suitable for advanced cases with PIK3CA mutatio···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：281
The combination of Alpelisib and fulvestrant specifically targeted patients with advanced breast cancer with HR/HER2- and PIK3CA mutations significantly prolongs progression-free s···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：262
Koselugois a multifunctional targeted therapy drug, which can be used as a small molecule MEK inhibitor for the treatment of low-grade serous ovarian cancer, etc., and as a tyrosin···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：256
Koselugo is a targeted therapy that targets specific cancers by inhibiting the activity of key enzymes to block the growth of cancer cells.Which drugs interact with KoselugoThere a···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：290
Koselugo is a targeted therapy drug for the treatment of low-grade serous ovarian cancer, neurofibromas, etc., by inhibiting MEK protein kinase and RET tyrosine kinase activity.Wha···【more】
Article source：Captain MedicineRelease date：2024-08-23Recommended：300
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1632025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4002024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1552025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1752025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1552025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1892025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1702025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1652025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
